The continuous efforts being made globally by multiple companies to find more treatment options for Autism has led to significant advancements over the past few years. To gain an in-depth understanding of these developments as far as the Treatment of Autism is concerned, DelveInsight has come up with a detailed report titled “Autistic Disorder Pipeline Insight 2023”.
This report gives an inside look at the current state and progress of more than 20 companies studying over 25 pipeline drugs in the Autistic Disorder landscape. It also sheds light on the different stages, routes of administration, and molecule types of these potential drugs. Using this information, researchers and doctors can stay on top of the advancements in this field and even learn potential future treatment options for Autism.
Top Findings from the Report
With more than 20 active players engaged in the development of over 25 pipeline therapies, DelveInsight’s report on the Autistic Disorder pipeline showcases a thriving market.
Top players in the Autistic Disorder Market include Eli Lilly and Company, Scioto Biosciences, AbbVie, Yamo Pharmaceuticals, Axial Therapeutics, Jazz Pharmaceuticals, Hoffmann-La Roche, and others.
Current drug developments that are promising in various stages of progression for treating Autistic Disorder include Aripiprazole, Memantine HCl, Aripiprazole Oral Solution, and others.
In August 2023, Otsuka Pharmaceutical Development & Commercialization Inc. revealed plans for phase 3 clinical trials of Brexpiprazole. The objective was to assess the potential efficacy of brexpiprazole in children participants (ages 5-17) with Autism.
A phase 2 trial for the ML-004 (IR)/(ER) tablet was announced by MapLight Therapeutics in August 2023. This study will be a randomized, placebo-controlled trial and will enroll 150 individuals with ASD who are adolescents or adults.
Specifics of the drugs
The specifics of the drugs mentioned in the report are thorough & include their mechanism, clinical studies, and NDA approvals, in other words, if the drug is already on the market or if it’s still in development. It also includes licensing agreements for the drug. Other topics discussed in this document include merger and acquisition activities, funding initiatives, designations, and other pertinent information related to the product.
Scope of the Report
- Scope of Inclusion – Worldwide
- Assessment of Therapeutics for Autism based on Product Types includes Monotherapy and combination Therapy. It also includes Hybrid Therapy.
- Clinical Development Stages include the Discovery, Pre-Clinical, and Clinical Trial phases.
- Companies involved in treatment include Scioto Biosciences, AbbVie, Yamo Pharmaceuticals, Jazz Pharmaceuticals, Hoffmann-La Roche, and more.
About delve-insight
For those unfamiliar with Delveinsight, it is a research company that assists clients in making well-informed business decisions. With a team of seasoned industry professionals and an extensive knowledge of the life sciences and healthcare industries, DelveInsight delivers personalized research solutions and valuable insights to businesses worldwide. You can reach them for reliable, precise, and up-to-the-minute intelligence to stay ahead of the rising trends.
Autism Treatment Option
As the efforts to find more treatment options for Autism continue globally, Nevada Autism Center is also dedicated to making a difference in the lives of Autistic kids. We provide top-notch ABA therapy to individuals with Autism and their families, thus maneuvering through the complexities of ASD. Our team is updated in the latest developments in Autism treatment, ensuring that our services are evidence-based and up-to-date.
